ArticleJACC. Case reports2026
Immune Checkpoint Inhibitor-Associated Myocarditis Mimicking Takotsubo Cardiomyopathy.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune-Checkpoint-Inhibitor-Related Cardiovascular Toxicities in Cancer: A Mechanistic Review of Molecular Pathways with AI-Assisted Literature Clustering.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPembrolizumab-induced myocarditis is a rare but life-threatening immune-related adverse event. CASE SUMMARY: A 72-year-old woman with stage IV EGFR exon 19 deletion-positive left lung adenocarcinoma received osimertinib as first-line therapy. After disease progression, she underwent pembrolizumab plus pemetrexed-carboplatin as second-line therapy, then docetaxel plus ramucirumab as third-line therapy. She presented with nausea and anorexia, and electrocardiograms revealed widespread ST-segment elevation. Coronary angiography revealed no significant stenosis; left ventriculography revealed an apical ballooning pattern. Although Takotsubo cardiomyopathy was suspected, endomyocardial biopsy confirmed pembrolizumab-induced myocarditis. High-dose corticosteroids improved her cardiac function; however, the underlying malignancy progressed. DISCUSSION: Immune checkpoint inhibitor-associated myocarditis can mimic atypical Takotsubo cardiomyopathy, with persistent changes on electrocardiograms or elevated biomarkers, warranting endomyocardial biopsy for diagnosis and treatment with steroids. TAKE-HOME MESSAGE: In patients receiving immune checkpoint inhibitors, consider myocarditis in atypical Takotsubo presentations; biopsy and early steroids improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.